OncoResponse
WA - SeattleBiotechnology
Focus: OncoResponse is an immuno-oncology antibody company focused on early-stage cancer therapeutics based in Seattle. The company is in pre-revenue biotech stage with two Phase 1/2 programs in active development.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About OncoResponse
AI assessmentNot HiringNo open roles listed right now. Follow OncoResponse to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OR2805
CancerClinical Trials (1)
NCT05094804A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
Phase 1/2Help build intelligence for OncoResponse
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.